


AhR modulator-1

| | |
|---------------------------|---|
| Cat. No.: | HY-135671 |
| CAS No.: | 118174-38-2 |
| Molecular Formula: | C ₁₃ H ₇ Cl ₃ O |
| Molecular Weight: | 285.55 |
| Target: | Aryl Hydrocarbon Receptor; VEGFR; Estrogen Receptor/ERR |
| Pathway: | Immunology/Inflammation; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | | | | | | | | | |
|-------------------------------------|---|---------------|--|----------------|-----------------------------|------------------|--|---------|--|
| Description | AhR modulator-1 (compound 6-MCDF) is a selective and orally active aryl hydrocarbon receptor (AhR) modulator. AhR modulator-1 inhibits metastasis, in part, by inhibiting prostatic VEGF production prior to tumor formation. AhR modulator-1 also possess anti-estrogenic properties in rat uterus ^[1] . | | | | | | | | |
| IC₅₀ & Target | Aryl hydrocarbon receptor (AhR) ^{[1][2]} Prostatic VEGF ^[1] Estrogenic ^[1] | | | | | | | | |
| In Vitro | <p>AhR modulator-1 (6-MCDF; 0.1-10 μM; 48-96 hours; ASPC-1 cells) treatment exhibits dose-dependent growth inhibitory effects with growth inhibitory effects of 26, 43 and 99% at concentrations of 0.1, 1 and 10 μM, respectively^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>ASPC-1 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.1 μM, 1 μM and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours, 72 hours, 96 hours</td> </tr> <tr> <td>Result:</td> <td>Exhibited dose-dependent growth inhibitory effects.</td> </tr> </table> | Cell Line: | ASPC-1 cells | Concentration: | 0.1 μM, 1 μM and 10 μM | Incubation Time: | 48 hours, 72 hours, 96 hours | Result: | Exhibited dose-dependent growth inhibitory effects. |
| Cell Line: | ASPC-1 cells | | | | | | | | |
| Concentration: | 0.1 μM, 1 μM and 10 μM | | | | | | | | |
| Incubation Time: | 48 hours, 72 hours, 96 hours | | | | | | | | |
| Result: | Exhibited dose-dependent growth inhibitory effects. | | | | | | | | |
| In Vivo | <p>AhR modulator-1 (6-MCDF; 0-40 mg/kg; oral administration; daily; for 12 weeks; C57BL/6-Tg(TRAMP)8247Ng/J mice) treatment reduces the frequency of pelvic lymph node metastasis in mice fed the 40 mg/kg diet. And serum VEGF concentrations are also reduced. Prostate tumor incidence and size are not significantly reduced^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP) mice (8-week-old)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0 mg/kg, 10 mg/kg, 40 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration; daily; for 12 weeks</td> </tr> <tr> <td>Result:</td> <td>The frequency of pelvic lymph node metastasis was reduced 5-fold in mice fed the 40 mg</td> </tr> </table> | Animal Model: | C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP) mice (8-week-old) ^[1] | Dosage: | 0 mg/kg, 10 mg/kg, 40 mg/kg | Administration: | Oral administration; daily; for 12 weeks | Result: | The frequency of pelvic lymph node metastasis was reduced 5-fold in mice fed the 40 mg |
| Animal Model: | C57BL/6-Tg(TRAMP)8247Ng/J (TRAMP) mice (8-week-old) ^[1] | | | | | | | | |
| Dosage: | 0 mg/kg, 10 mg/kg, 40 mg/kg | | | | | | | | |
| Administration: | Oral administration; daily; for 12 weeks | | | | | | | | |
| Result: | The frequency of pelvic lymph node metastasis was reduced 5-fold in mice fed the 40 mg | | | | | | | | |

/kg diet. Serum VEGF concentrations were also reduced.

REFERENCES

- [1]. Fritz WA, et al. The selective aryl hydrocarbon receptor modulator 6-methyl-1,3,8-trichlorodibenzofuran inhibits prostate tumor metastasis in TRAMP mice. *Biochem Pharmacol.* 2009 Apr 1;77(7):1151-60.
- [2]. Koliopanos A, et al. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. *Oncogene.* 2002 Sep 5;21(39):6059-70.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA